From the measurements carried out, a significant decrease in immunoreactive insulin was found in group 1, the group with obesity and type 2 diabetes, with the daily intraperitoneal application of WAY163909 (1 mg/kg), p < 0.01. This evidence concerns the gene INS and Obesity.